Brief: Bridge Biotherapeutics Presents Phase 2A Clinical Trial Results For Bbt-401, A Drug Candidate To Treat Ulcerative Colitis
20/02/2023 23:28
Feb 20 (Reuters) - Bridge Biotherapeutics Inc
288330.KQ :
* BRIDGE BIOTHERAPEUTICS PRESENTS PHASE 2A CLINICAL TRIAL
RESULTS
FOR BBT-401, A DRUG CANDIDATE TO TREAT ULCERATIVE COLITIS
* BRIDGE BIOTHERAPEUTICS INC - BBT-401 MEETS SAFETY
ENDPOINTS
ACHIEVED IN PREVIOUS CLINICAL STUDIES
* BRIDGE BIOTHERAPEUTICS INC - DRUG CANDIDATE DID NOT
ACHIEVE AN
IMPROVED CLINICAL RESPONSE COMPARED TO THE PLACEBO STUDY GROUP
* BRIDGE BIOTHERAPEUTICS INC - 54.5% OF THE TREATMENT COHORT
EXHIBITED A VALID TREATMENT RESPONSE TO ORALLY ADMINISTERED
BBT-401
* BRIDGE BIOTHERAPEUTICS - SAFETY,TOLERABILITY PROFILE IN
PHASE 2A
STUDY CONSISTENT WITH SAFETY PROFILE OF BBT-401 DEMONSTRATED IN
PREVIOUS STUDIES
Source text for Eikon: urn:newsml:reuters.com:*:nPnWMmgDa
Further company coverage: 288330.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Parataxis Korea
See all newsBrief: Parataxis, Bridge Biotherapeutics Ink Deal to List Bitcoin Treasury Firm on Korea's KOSDAQ
Brief: Bridge Biotherapeutics Announces Completion Of Enrollment In The Phase 2A Clinical Study Of BBT-877 For The Treatment Of Idiopathic Pulmonary Fibrosis
Brief: Bridge Biotherapeutics Launches A Research Collaboration With Emory University School Of Medicine
Brief: Bridge Biotherapeutics Announces A Research Collaboration With The University Of Colorado School Of Medicine
Brief: Bridge Biotherapeutics To Conduct Capital Increase Of 2 Billion Won For Operational Funds